22157.jpg
Lipid Nanoparticles for Gene Therapy Market Research 2024: Gene Therapy Sales are Projected to Exceed $10bn by 2027 - LNPs have Gained Popularity as Carriers for Gene Therapies
September 18, 2024 09:05 ET | Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy - Lipid nanoparticles" report has been added to ResearchAndMarkets.com's offering.This report discusses the developing trend and...
oxb new logo.png
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
September 18, 2024 07:00 ET | OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
Gene Therapy
Gene Therapy Market Report 2024- 2035, by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Leading Market Players and Sales Forecast
September 17, 2024 08:48 ET | Research and Markets
Dublin, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Market, 6th Edition: Industry Trends and Global Forecasts to 2035 - Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene...
Klotho Neurosciences, Inc.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
September 17, 2024 06:30 ET | ANEW MEDICAL, INC.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Avid Logo June 2022.jpg
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
September 12, 2024 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
genespire-logo def-01.jpg
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
September 12, 2024 07:00 ET | Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
genespire-logo def-01.jpg
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
September 12, 2024 01:00 ET | Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
Avid Logo June 2022.jpg
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
September 09, 2024 16:05 ET | Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...
MDA Kickstart
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
September 09, 2024 09:00 ET | Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
ocugen_4C_LOGO (002).png
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
September 09, 2024 06:30 ET | Ocugen
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...